Topic

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Videos

Life sciences CEOs are boosting AI spending, focusing on workforce upskilling, and tackling ethical challenges to drive innovation and product development.

KPMG CEO Outlook: How Pharma Is Navigating AI, Regulatory Demands, and Supply Chain Risk

 is vice-president, Product Management for AI & Data at 

, based in London. A data science actuary, he has built his career in fintech and health-tech, and specializes in AI-powered, data-driven, yet human-centric product innovation. He previously led an AstraZeneca digital incubator and today remains on the board of a health charity, Scleroderma & Raynaud's UK (SRUK), which is dedicated to improving the lives of people affected by those conditions in the UK.

Articles

In the conclusion of this three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part Three: Tapping Agentic AI’s Potential

In this continuation of a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part Two: Agentic AI’s Adoption in Life Sciences

Jennifer Markarian is a contributing editor for 

Advances in digital technologies offer effective data handling for bio/pharma manufacturing.

Optimizing Data Use for Digital Transformation

In a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part One: The Evolution of AI

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet

Survey responses indicate that bio/pharma faces tariff-driven rising costs and supply strain, with firms aiming to boost compliance and diversification and seeking stable trade and R&D support.

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.

Survey: Impacts of Tariffs and Trade Policy on the Bio/pharmaceutical Industry

Lack of skills in the AI realm was a distant second among those surveyed about the biggest barrier to innovation while using the technology.

Agentic AI Growth Predicted, but More Than Half of Pharma Still Resisting Change: Report

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

In an interview with Pharmaceutical Technology®, Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.

Data and Artificial Intelligence